+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 60Years
All Genders
ID06924658

Evaluating Metformins Effect on Clinical Outcomes in Adults with Gout

Led by Mostafa Bahaa · Updated on 2026-09-30

70

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Gout is the most common crystal arthropathy and a leading cause of inflammatory arthritis, often causing severe joint pain and swelling. It is linked to reduced quality of life, functional disability, and increased risks of mortality and other health problems. Researchers are exploring how metformin, a drug commonly used to manage diabetes, might impact clinical outcomes in patients with gout. The study compares two groups of gout patients one receiving a placebo alongside standard gout treatments, and another receiving metformin at a dose of 1000 mg per day with the same standard treatments. The trial is randomized and double-blind, meaning neither participants nor researchers know who receives metformin or placebo. The study lasts for three months, focusing on treatment effects. Participants will undergo clinical assessments to evaluate disease activity during the three-month treatment period. Researchers will monitor how the treatments affect the participants and measure outcomes related to gout symptoms. Safety and tolerability will also be observed throughout the study to gather information on metformins impact in this patient group.

CONDITIONS

Brief Title

Metformin in Safety and Efficacy in Gouty Patients

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here